Westlake Village BioPartners
Venture capitalLos Angeles · Pre-Seed–Series A · 13 people tracked
Also known as WESTLAKE BIOPARTNERS, LLC
Investment thesis
The firm takes a people-first, company-creation approach to life science investing, crafting and incubating a concentrated portfolio of biotech companies around world-class entrepreneurs. Deeply embedded in the Los Angeles biotech ecosystem it helped catalyze, it is intentionally scaled to offer close, hands-on relationships with founders, guiding companies from ideation and preclinical research through clinical and commercial impact. The firm emphasizes empowering the right people, providing personal attention, capital, and access to a complementary network of innovation and community, with the goal of turning scientific breakthroughs into life-saving medicines that address the greatest unmet patient needs in California and beyond.
Source: firm website, verified Aug 3, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 14 of 29 portfolio companiesBiotech ×13Healthtech ×5Medical Devices ×5Digital Health ×4AI & Machine Learning ×2Deep Tech ×1
HQs:United States×11
Investments · 29 tracked
founders shown can be your intro pathBiotechMenlo Park, US
David Mott(Director)Rekha Hemrajani(Executive Officer)Richard Rodgers(Director)Gordon Ringold(Director)Merdad Parsey(Executive Officer, Director)James Young(Director)
Board seatBeth Seidenberg· per SEC Form D · $80M raise · filed Jan 2021
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.
BiotechDeep TechDigital HealthMedical Devices
Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inAmit Mehta(Director)Laura Norris(Executive Officer, Director)Joseph G. Azofeifa(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)
Board seatDavid AllisonMira Chaurushiya· per SEC Form D · $35.3M raise · filed Nov 2025
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
James Ahlers(Executive Officer)Kenneth Drazan(Executive Officer, Director)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)Sean Parker(Director)
Board seatBeth Seidenberg· per SEC Form D
HealthtechSeattle, US
Michael Hite(Director)John D. Hoekman(Executive Officer, Director)Stewart Parker(Director)
Board seatDavid Allison· per SEC Form D · $1.9M raise · filed Apr 2021
BiotechThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardJim Tananbaum(Director)Deborah Palestrant(Director)Kevin Raidy(Director)
Board seatBeth Seidenberg· per SEC Form D · $150M raise · filed Feb 2025
Woburn, US
Board seatDavid Allison· per SEC Form D · filed Jul 2021
BiotechSan Francisco, US
Nisha Marathe(Director)Kristine M Ball(Executive Officer, Director)David Allison(Director)Keno Gutierrez(Director)David Morris(Director)Steve James(Director)
Board seatDavid Allison· per SEC Form D · $42.2M raise · filed May 2021
South San Francisco, US
Board seatBeth Seidenberg· per SEC Form D · $125M raise · filed Oct 2025
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
K. Christopher Garcia
Clinical stage company developing a small molecule pan-ROCK inhibitor targeting pulmonary and fibrotic indications.
AllRock Bio develops novel drug therapies targeting pulmonary hypertension and fibrotic lung diseases, with a lead program focused on ROCK inhibitors for pulmonary arterial hypertension and related conditions.
BiotechDigital HealthMedical Devices
A clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer.
Borealis develops RNA medicines to treat kidney diseases.
BiotechDigital Health
A clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical Devices
Beth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Matthew Fust(Director)Carl Gordon, Ph.D.(Director)Nancy Stagliano, Ph.D.(Director)Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
A patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases.
BiotechSan Diego, US
Kevin Forrest, Ph.D.(Executive Officer, Director)
BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)
A patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
Clinical-stage biotech developing non-opioid pain medicines targeting pain transduction.
Clinical-stage biotechnology company using AI and machine learning to develop precision medicines for neurological and autoimmune diseases.
Clinical stage company developing novel treatments for fibrotic diseases.
Developing platform approaches to discover selective inhibitors of challenging protein targets.
Biotech developing therapies for rare diseases.
Cell therapy company now part of Kite, a Gilead Company, focused on treating cancer.
Preclinical stage company developing next-generation biologics for migraine prevention.
Clinical stage biotech developing first-in-class therapies for rare blood disorders, starting with von Willebrand disease.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Westlake Village BioPartners invest at?
- Westlake Village BioPartners invests at the Pre-Seed, Seed, Series A stages.
- What is Westlake Village BioPartners's typical check size?
- Westlake Village BioPartners typically writes checks of $100K – $5M.
- What sectors does Westlake Village BioPartners focus on?
- Westlake Village BioPartners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Westlake Village BioPartners located?
- Westlake Village BioPartners is headquartered in Los Angeles, US.
- Does Westlake Village BioPartners lead rounds?
- Westlake Village BioPartners typically participates in rounds rather than leading them.
Images
Co-investors · 13
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Celesta Capital is a venture capital firm that invests in deep tech companies at the forefront of science and engineering.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
▶1 more co-investors
Firms observed investing alongside Westlake Village BioPartners, from public investor directories. Shared companies are the overlap with Westlake Village BioPartners's recorded portfolio.
Similar investors
Future Positive Capital is an investment firm backing entrepreneurs building companies that address major global challenges and shape more sustainable, preferable futures.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.